A top 10 pharma company faced challenges in standardizing safety surveillance across Pharma, Vaccine, and Consumer Health units, including consolidating signal teams, facilitating a divestment,
In her latest article for IPI, Qinecsa President, Humaira Qureshi discussed the practical challenges of integrating medical devices into pharmacovigilance portfolios, the obligations of device
A head of our first exhibition at the DIA Global Annual Meeting, taking place in San Diego from June 16th-20th, Qinecsa spoke with Outsourcing-Pharma about our
Following her attendance at DIA Europe 2024, Humaira Qureshi, President of Qinecsa Solutions, spoke with PharmaPhorum about the transforming pharmacovigilance landscape, the potential barriers and
Drug safety is critical to protect patients and consumers exposed to pharmaceutical development and commercialized drugs. Although the principal framework for Drug Safety and PV
Qinecsa specializes in technology-led, end-to-end pharmacovigilance solutions, built on over 20 years of heritage expertise. As a trusted global partner, we combine best-in-class technology with
Reportum is a unified adverse event platform managing both digital and analogue intake from all sources. It offers a digital-first experience for consumers and healthcare
Qinecsa provide quality and compliance services to support clients in audit and inspection readiness, SOP writing, data privacy adherence, pharmacovigilance training, PSMF maintenance and CAPA
Qinecsa is a leading global provider of end-to-end pharmacovigilance solutions. Our team of pharmacovigilance specialists leverage technology solutions to deliver all aspects of global case
Qinecsa provides tailored signal detection and risk management services for clinical and commercial products, including associated benefit-risk management activities. With diverse therapeutic expertise and industry-leading
